SDZ281-977

SKU: orb1706647

Description

SDZ281-977 (SDZ-LAP 977) is a Lavendustin A derivative with anticancer and anti-proliferative properties. It has demonstrated inhibitory effects on the growth of human vulvar carcinoma cells in vitro, making it a compound of interest for oncology research and kinase inhibition studies.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 150779-71-8
• MW: 316.35
• Purity: 99.64% (May vary between batches)
• Formula: C₁₈H₂₀O₅
• SMILES: COC(=O)c1cc(CCc2cc(OC)ccc2OC)ccc1O
• Target: EGFR
• Solubility: DMSO:80 mg/mL (252.88 mM)

Bioactivity

• In Vivo:
  Intravenous administration of SDZ 281-977 (1-10 mg/kg) for 4 weeks in nude mice with A431 human vulvar carcinomas results in dose-dependent tumor growth inhibition. Additionally, oral administration of SDZ 281-977 (30 mg/kg) leads to a 54% inhibition of A431 tumor growth after 3 weeks of treatment .
• In Vitro:
  The anticancer activity of SDZ 281-977 is evaluated in nude mice with human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells), and MDA-MB-231 (breast carcinoma cells). The IC50 values for growth inhibition of A431, MIA PaCa-2, and MDA-MB-231 cells are 0.21 μM, 0.29 μM, and 0.43 μM, respectively .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

EGFR, SDZ281 977, SDZ281977, SDZ-281-977, SDZ281-977, SDZ-LAP 977, SDZ-LAP977, SDZ-LAP-977

Compound Identifiers

PubChem CID

9818362